CPHL Pharmaceuticals: Major
Health Technology
Mkt Cap
18.1B
P/E (TTM)
16.48
EPS
3.90
ROE
13.28%
Div Yield
4.42%
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | ||
|---|---|---|---|---|---|---|
| Total Revenue | 13.15B | 12.41B | 12.40B | 9.78B | 5.80B | |
| Cost of Goods Sold | -11.24B | -10.91B | -10.96B | -8.48B | -5.05B | |
| Gross Profit | 1.92B | 1.50B | 1.44B | 1.30B | 742.86M | |
| SG&A Expenses | -384.67M | -358.09M | -330.38M | -367.45M | -198.64M | |
| Research & Development | -2.79M | 0 | -9.67M | -10.98M | — | |
| Depreciation | -168.09M | -138.22M | -90.59M | -76.83M | -65.69M | |
| Other Operating Expense | -27.05M | -28.92M | -18.86M | -20.66M | -8.52M | |
| Total Operating Expense | -11.65B | -11.30B | -11.31B | -8.87B | -5.26B | |
| Operating Income (EBIT) | 1.50B | 1.11B | 1.09B | 907.62M | 535.70M | |
| Interest Income | 181.89M | 358.71M | 259.51M | 203.71M | 0 | |
| Interest Expense | -323.63M | -299.91M | -140.55M | -64.19M | -40.78M | |
| Equity in Earnings | 0 | 0 | 0 | 0 | — | |
| Other Non-Operating Income | -8.68M | 76.71M | -240.91M | 3.75M | 4.82M | |
| Total Non-Operating Income | -150.42M | 167.84M | -136.23M | 152.95M | -35.95M | |
| Pre-Tax Income | 1.35B | 1.28B | 955.72M | 1.06B | 499.75M | |
| Income Tax | -462.47M | -444.44M | -297.74M | -406.88M | -147.98M | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | |
| Net Income | 892.04M | 833.46M | 657.98M | 653.69M | 351.77M | |
| EBITDA | 1.67B | 1.25B | 1.18B | 984.45M | 601.39M | |
| EPS (Basic) | 3.90 | 3.65 | 2.88 | 2.88 | 4.22 | |
| EPS (Diluted) | 3.90 | 3.65 | 2.88 | 2.88 | 2.15 | |
| Gross Margin | 14.57% | 12.06% | 11.63% | 13.25% | 12.82% | |
| Operating Margin | 11.44% | 8.95% | 8.81% | 9.28% | 9.24% | |
| EBITDA Margin | 12.72% | 10.06% | 9.54% | 10.07% | 10.38% | |
| Pre-Tax Margin | 10.30% | 10.30% | 7.71% | 10.84% | 8.62% | |
| Net Margin | 6.78% | 6.72% | 5.31% | 6.68% | 6.07% |